Released Mar 26, 2026, after the close
10-K filed Mar 26, 2026, 85 days after period end · 0001683168-26-002257
Q4 2025 · 10-K
derived · Computed from the longer spans the company filed.
Revenue—
Net Income-$4.55M-$4.55M derivedN/M vs Q4 2024N/M vs Q3 2025
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$4,688,473N/M
Operating Cash Flowderived-$3,736,043N/M
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-K.
Same quarter
| Metric | Q4 2025dderived from reported figures | Q4 2024dderived from reported figures | Q4 2023dderived from reported figures |
|---|---|---|---|
| Net Income | -$4.55M | -$6.45M | -$7.61M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Actuate Therapeutics, Inc. · CIK 1652935 · Engraved from SEC EDGAR